Transgene Updates Its Individualized Cancer Vaccine Program on November 9: TG4050 Maintains 100% Disease-Free Survival After More Than Three Years in Head and Neck Cancer, and the TG4070 Lung Cancer Trial Has Started
STRASBOURG, France — Transgene (Euronext Paris: TNG) provided a business update on November 9, 2026, on its myvac-based individualized neoantigen therapeutic vaccine assets TG4050 and TG4070, together with its financial position as of September 30, 2026.
The company said strong Phase 1 data from the randomized Phase 1/2 trial of TG4050 (NCT04183166), demonstrating clinical proof of principle in patients with early-stage head and neck squamous cell carcinoma at high risk of relapse following surgery and (chemo)-radiotherapy, have been published in Nature Communications. TG4050 showed a favourable safety profile and induced persistent neoantigen-specific T cell responses, with a 100% disease-free survival rate sustained after more than three years of follow-up. The Phase 2 part of the study is ongoing; the company expects first immunological data by year end, aims to present them at a scientific conference in 2027, and expects to communicate topline results from the Phase 2 trial by the end of the first quarter of 2028.
For lung cancer, the company has initiated a randomized Phase 1 trial evaluating TG4070 in combination with nivolumab in patients with resected non-small cell lung cancer following neoadjuvant nivolumab plus chemotherapy (EUCT 2025-520946-31-00). In the release, Transgene described itself as a biotechnology company developing its myvac individualized neoantigen therapeutic vaccine platform to prevent cancer recurrence, alongside a portfolio of viral vector-based candidates.
https://www.morningstar.com/news/globe-newswire/1001302669/transgene-reports-continued-clinical-progress-and-q3-2026-financial-update （Transgene 2026年11月9日临床进展与第三季财务更新公告）
科学
—-
Published by GSM · USA (original Chinese edition)
Photo: Wikipedia/Wikimedia Commons 词条主图：Transgene
